August 2015

New Product - Daklinza

Daklinza (daclatasvir) is a highly selective inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A) replication complex. Daklinza is indicated in combination with other medicinal products for the treatment of chronic HCV infection in adults with compensated liver disease (including cirrhosis). The combination of Daklinza with peginterferon alfa and ribavirin is contraindicated in women who are pregnant or may become pregnant and men whose female partners are pregnant because of the risks of birth defects and foetal death associated with ribavirin. Daklinza is also contraindicated in combination with drugs that strongly induce CYP3A4 and thus may lead to lower exposure and loss of efficacy of Daklinza. Contraindicated drugs include, but are not limited to, phenytoin, carbamazepine, oxcarbazepine, phenobarbital, rifampicin, rifabutin, dexamethasone and St John’s wort (Hypericum perforatum). Daklinza is available as 30 mg and 60 mg tablets in packs of 28’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au